11-05-2020
Bill Perry / Shutterstock.com
The US Court of Appeals for the Federal Circuit has affirmed a generic maker’s victory over pharmaceutical company Eagle Pharmaceuticals in a case involving cancer drug Belrapzo (bendamustine hydrochloride injection).
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
US Court of Appeals for the Federal Circuit, generics, Eagle Pharmaceuticals, Belrapzo, Slayback Pharma, patent infringement,
Teva and Eagle try to block Bendeka generic
01-07-2021
Fed Circuit limits venue options for generic patent suits
06-11-2020
FDA warns of ‘grave’ knock-on effects from Eagle decision
29-05-2020
FDA approves Hikma’s Vascepa generic
26-05-2020
Cochlear's $268m damages bill stands, says Fed Circuit
20-05-2020
Fed Circuit rejects Biogen’s plea in MS drug dispute
23-04-2020
Eli Lilly and Eagle Pharma settle antitrust and infringement claims
18-12-2019
